The latest lymphoma news
An interim analysis of the TRANSFORM trial comparing CAR T-cell therapy lisocabtagene maraleucel (liso-cel) to…
Follow-up data from the Phase II ZUMA-5 trial showed a long-term survival benefit with axicabtagene ciloleucel (axi-cel)…
A phase I/II trial for the experimental drug mosunetuzumab met its primary endpoint, leading to…
Mutations in a crucial gene are the key reason that chemotherapy fails in some patients…
Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by…
Standard therapy for advanced recurring aggressive, haematological malignancies, such as leukaemias and lymphomas, have a…
To understand blood cancer, it is important to know it mainly affects the bone marrow,…
A survey by the charity Blood Cancer UK has found that over half of UK…
Research led by the University of Southampton, UK, has revealed a new fundamental feature of…
MUSC Hollings Cancer Center (USA) was one of 28 clinical sites around the world that…